Clinical Trials Logo

Filter by:
NCT ID: NCT03407482 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Start date: January 11, 2018
Phase: Phase 2
Study type: Interventional

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

NCT ID: NCT03397485 Completed - Undernutrition Clinical Trials

Fortified Milk, Growth and Micronutrient Status in Mexican Toddlers (MilkGrowth)

Start date: January 1, 2011
Phase: N/A
Study type: Interventional

The objective of the present study was to assess the effect of a growing-up milk on growth and micronutrient status in children 12 to 30 months of age. The study was conducted in Cuernavaca, the state capital of Morelos, Mexico. The investigators included children who attended day-care centers. These day- care centers are part of a national government program which main objective is to support working mothers and those who intend to work and do not have access to a health service and are at risk of poverty. The study described herein is a randomized, parallel, double-blind, controlled trial by administration of growing up milk (GM) and fortified milk (FM). Results showed a significant improvement in linear growth in both supplemented groups, with no statistical difference between treatments. By using an artificial, population-based comparison group, the investigators conclude that this improvement was attributable to the supplements.

NCT ID: NCT03393286 Recruiting - Zika Virus Clinical Trials

ZIKAlliance Children Cohort (ZIKAllianceCH)

ZIKAllianceCH
Start date: January 15, 2018
Phase: N/A
Study type: Observational

The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. We will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome.

NCT ID: NCT03391193 Active, not recruiting - Influenza Clinical Trials

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Start date: December 19, 2017
Phase: Phase 3
Study type: Interventional

The aim of the study is to to assess the immunogenicity and safety of a quadrivalent influenza vaccine in a multi-dose presentation compared to a quadrivalent influenza vaccine in single-dose presentation, in children aged 6 months to 17 years.

NCT ID: NCT03390504 Not yet recruiting - Urothelial Cancer Clinical Trials

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Start date: January 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after one prior treatment.

NCT ID: NCT03389711 Recruiting - Clinical trials for Rheumatoid Arthritis

INCMNSZ - Rheumatoid Arthritis Cohort

IRAC
Start date: February 4, 2004
Phase: N/A
Study type: Observational

Identify Rheumatoid Arthritis patients diagnose within first 12 months since the beginning of the disease related symptoms. Initiate proper treatment according to international standards in order to achieve remission/low disease activity status.

NCT ID: NCT03379675 Not yet recruiting - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the antiviral effect of JNJ-53718678 at 2 dose levels (80 milligrams [mg] and 500 mg) once daily for 7 days in adults with Respiratory Syncytial Virus (RSV) infection, as measured by RSV viral load in nasal secretions by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay.

NCT ID: NCT03377374 Not yet recruiting - Pharyngitis Clinical Trials

L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis

Start date: December 28, 2017
Phase: N/A
Study type: Interventional

RCT in children (6m to 5y) with pharyngitis and/or tonsillitis who will be allocated to receive for 10 days L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289) at a dose of 2x10^8 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) or placebo drops, as treatment for clinical condition. Duration of symptoms and reduction of pain (odynophagia) severity during treatment will be measured as primary outcome

NCT ID: NCT03376321 Recruiting - Influenza A Clinical Trials

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Start date: January 3, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.

NCT ID: NCT03375411 Recruiting - Clinical trials for Coronary Artery Disease

First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.

Start date: December 30, 2017
Phase: N/A
Study type: Interventional

This is a First In Man study with the aim to know the safety and effectiveness of a novel bare metal stent (INC-1) in the treatment of de novo coronary lesions in patients with stable coronary angina and unique coronary lessions.